meta
|
evidence
oncology
Living systematic review and meta-analysis
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
2
MIBC - NA - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab alone
title
nivolumab alone
title
no additional treatment
title
placebo
title
IMvigor-010, 2021 NCT02450331 MIBC - NA - all population 406/403
CheckMate 274 (all population), 2017 NCT02632409 MIBC - NA - all population 353/356
Pathology:
MIBC - NA - all population;
MIBC - NA - all population
IMvigor-010, 2021
CheckMate 274 (all population), 2017
atezolizumab alone
1
T1
nivolumab alone
1
T1
no additional treatment
0
T0
placebo
0
T0